Enhancing Radiotherapie Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131

Although radiation therapy quality assurance (RTQA) is important in any clinical trial with a radiation therapy (RT) component, it is paramount in lymphoma trials for several reasons. As lymphoma RT has evolved to use smaller and more complex treatment fields such as involved-site radiation therapy (ISRT) and positron emission tomography (PET)-directed residual-site radiation therapy (pRSRT), accurate target delineation has become more challenging, especially when lymphoma patients comprise only a small proportion of most radiation oncologists’ clinical practice.